using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
Published 1 year ago • 125 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:52
improving the outcomes of transplantation with bispecific antibodies
-
2:00
the success story of bispecific and trispecific antibodies
-
1:10
how bispecific antibodies contribute to t-cell activation in aml
-
1:51
how to manage tumor flare after administration of bispecific antibodies
-
1:09
outpatient dosing of bispecific antibodies: what do clinicians need to consider?
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
1:09
assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with b-cell malignancies
-
3:05
using patient-derived organoids to investigate bispecific t-cell engager immunotherapy in fl
-
4:48
an insight into the management of cytopenias in mf
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
5:18
upfront treatment in transplant candidates
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
14:00
what are bispecific antibodies?
-
1:45
research into multispecific and multifunctional cell therapy products
-
0:45
cys-ser mutation-driven ibrutinib resistance and alternative btki’s under development
-
20:10
b cell research solutions in a nutshell [webinar]
-
1:05
third-party virus-specific t-cells targeting 6 viruses post-bmt